BNTX
BioNTech SE ADR (Nasdaq: BNTX) will report Q2 2026 financial results on August 4, 2026, with a conference...
Article Summary
HOLD- BioNTech SE ADR (Nasdaq: BNTX) will report Q2 2026 financial results on August 4, 2026, with a conference call and webcast at 8:00 a.m.
- ET for investors, financial analysts, and the general public to discuss financial results and provide a corporate update.
- BioNTech SE ADR will also introduce a new flag-stock feature for Portolios and Screener, allowing investors to flag stocks with color on the company's portfolio.
- The event will be followed by a live conference call for investors and analysts, with participants registering for the conference call by phone or via webcast.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 10.0% | 25% | 50.0 ptsMeets Minimum (10.0%) - Passes screener |
| EPS Growth Next 5Y ? | 2.0% | 25% | 10.0 ptsVery Weak (2.0%) - Minimal expectations |
| Target Price Upside ? | 31.8% | 20% | 85.0 ptsLarge Upside (31.8%) - Target: $121.48 vs Current: $92.18 |
| Gross Margin % ? | 73.3% | 15% | 100.0 ptsExceptional (73.3%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -25.7% | 15% | 80.0 ptsSolid Dip (-25.7%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About BNTX
- BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
- The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
- It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer.
- In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma.
- Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox.
- The company was incorporated in 2008 and is headquartered in Mainz, Germany.